Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped This study had an major amendment in 12/2006 introducing risk stratified sequential treatment (RSST). The modified protocol is registered with NCT00590447.

Conditions

Post-transplantation Lymphoproliferative Disorder

Interventions

DRUG: Rituximab
DRUG: CHOP

Sponsor

Charite University, Berlin, Germany